Kirksville, MONCT07711418Now EnrollingIRB Ready

Moderate-to-Severe Atopic Dermatitis Clinical Trial in Kirksville, MO

Access cutting-edge moderate-to-severe atopic dermatitis treatment through this phase 3 clinical trial at a research site in Kirksville. Study-provided care at no cost to qualified participants.

Sponsored by Nektar Therapeutics

Quick Self-Assessment

See if you qualify for this Kirksville location

Preparing your pre-screening questions…

Expert Care in Kirksville

Access moderate-to-severe atopic dermatitis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related moderate-to-severe atopic dermatitis treatment provided free

Apply for This Kirksville Location

Check if you qualify for this moderate-to-severe atopic dermatitis clinical trial in Kirksville, MO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Kirksville

    Convenient for MO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Kirksville site if eligible
  4. 4Begin participation

About This Moderate-to-Severe Atopic Dermatitis Study in Kirksville

This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall duration is approximately 15 months.

Sponsor: Nektar Therapeutics

Who Can Participate

Inclusion Criteria

Male or female patients, ≥ 12 years of age on the day of signing the informed consent form and weighing ≥ 40 kg prior to randomization at Baseline
Chronic atopic dermatitis (AD) defined as onset of AD signs and symptoms ≥ 12 months prior to Screening as determined by the Investigator through patient interview and/or review of medical history at the Screening Visit
Patients must meet the following AD severity criteria:
IGA score ≥ 3 (scale of 0 to 4) at Screening and Baseline
≥ 10.0% of BSA involvement at Screening and Baseline
EASI ≥ 16.0 at Screening and Baseline
Are candidates for systemic therapy and have history, documented by a physician and/or the Investigator, of inadequate response to existing topical medications within 6 months preceding Screening, or history of intolerance to a topical therapy
Provide written, informed consent to participate in the study and follow the study procedures, including compliance with the use of highly effective contraceptives

Exclusion Criteria

Are currently experiencing or have a history of concomitant skin conditions other than AD, including skin infection in the area affected by the patient's AD that requires treatment with systemic antimicrobial therapy
Are currently experiencing or have a history of unstable course of AD
History of chronic idiopathic urticaria at any time or urticaria from other causes within 4 weeks prior to randomization at the Baseline Visit.
Have a history of TCS use suggestive of a high risk for topical corticosteroid (TCS) withdrawal
Have received any of the following treatments at any time before Screening: aldesleukin; investigational IL-2 analog; systemic biologic; oral JAKi; or any prior investigational agent for AD
Have a current or recent acute, active infection

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Kirksville?

Yes, this clinical trial (NCT07711418) has an active research site in Kirksville, MO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Moderate-to-Severe Atopic Dermatitis Treatment Options in Kirksville, MO

If you're searching for moderate-to-severe atopic dermatitis treatment options in Kirksville, MO, this clinical trial (NCT07711418) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Kirksville research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced moderate-to-severe atopic dermatitis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all moderate-to-severe atopic dermatitis clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Kirksville, MO

See all rheumatoid arthritis clinical trials recruiting in Kirksville — not just this study.

Browse Rheumatoid Arthritis Trials in Kirksville →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsAtopic Dermatitis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Kirksville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Kirksville, MO